Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease

Pharmacogenetics and Genomics

Volumn 22, Issue 10, 2012, Pages 716-724

  Białecka, Monika ^a   Kurzawski, Mateusz ^a   Roszmann, Anna ^d,e   Robowski, Piotr ^d,e   Sitek, Emilia J ^d,e   Honczarenko, Krystyna ^b   Gorzkowska, Agnieszka ^f   Budrewicz, Sławomir ^g   Mak, Monika ^a   Jarosz, Monika ^c   GołÄ b Janowska, Monika ^b   Koziorowska Gawron, Ewa ^g   Droździk, Marek ^a   Sławek, Jarosław ^d,e  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Clinic of Neurology   (Poland)

^c Marie Curie Regional Hospital   (Poland)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e ST ADALBERT HOSPITAL   (Poland)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

dementia; genetic polymorphism; homocysteine; levodopa; Parkinson (tm)s disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CATECHOL METHYLTRANSFERASE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; REDUCED FOLATE CARRIER;

ADULT; ARTICLE; BLOOD SAMPLING; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; ENZYME ACTIVITY; FEMALE; FOLIC ACID BLOOD LEVEL; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HETEROZYGOSITY; HOEHN YAHR STAGING; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SCHWAB ENGLAND RATING SCALE; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84866328901     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835693f7     Document Type: Article

References (61)

1. Hobson P, Meara J, Ishihara-Paul L. The estimated life expectancy in community cohort of Parkinson's disease patients, with and without dementia, compared with the UK population. J Neurol Neurosurg Psychiatry 2010; 81:1093-1098.
2. Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J,Weintraub D. Cognitive impairment in nondemented Parkinson's disease. Mov Disord 2011; 26:2483-2495.
3. Schulz-SchaefferWJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010; 120:131-143.
4. Jokinen P, Brück A, Aalto S, Forsback S, Parkkola R, Rinne JO. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009; 15:88-93.
5. Halliday GN, McCann H. The progression of pathology in Parkinson's Disease. Ann N Y Acad Sci 2010; 1184:188-195.
6. Wolf DS, Gearing M, Snowdon DA. Progression of regional neuropathology in Alzheimer's disease and normal elderly: findings from the NUN Study. Alzheimer Dis Assoc Disord 1999; 13:226-231. (Pubitemid 30011381)
7. Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation 2011; 8:1-26.
8. Grammas P, Martinez J, Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med 2011; 13:1-19.
9. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, Toledo JB, et al. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord 2009; 24:1437-1444.
10. Dorszewska J, Florczak J, Rozycka A, Kempisty B, Jaroszewska-Kolecka J, Chojnacka K, et al. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases. Acta Neurobiol Exp (Wars) 2007; 67:113-129. (Pubitemid 47066464)
11. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006; 580:2994-3005. (Pubitemid 43744523)
12. Minagawa H, Watanabe A, Akatsu H, Adachi K, Ohtsuka C, Terayama Y, et al. Homocysteine, another risk factor for Alzheimer disease, impairs apolipoprotein E3 function. J Biol Chem 2010; 285:38382-38388.
13. Zoccolella S, dell'Aquila C, Specchio LM, Logroscino G, Lamberti P. Elevated homocysteine levels in Parkinson's disease: is there anything besides L-dopa treatment? Curr Med Chem 2010; 17:213-221.
14. Mattson MP. Gene-diet interactions in brain aging and neurodegenerative disorders. Ann Intern Med 2003; 139:441-444. (Pubitemid 38120873)
15. Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006; 66:1941-1943. (Pubitemid 44049836)
16. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG,Wolf PA. Effects of L-dopa on plasma homocysteine in PD patients. Relationship to B-vitamin status. Neurology 2003; 60:1125-1129. (Pubitemid 36418772)
17. Zoccolella S, Lamberti SV, Iliceto G, Santamato A, Lamberti P, Logroscino G. Hyperhomocysteinemia in L-dopa treated patients with Parkinson's disease: potential implications in cognitive dysfunction and dementia? Curr Med Chem 2010; 17:3253-3261.
18. Tunbridge EM, Harrison PJ,Warden DR, Johnston C, Refsum H, Smith AD. Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:996-999.
19. Białecka M, Robowski P, Honczarenko K, Roszmann A, Sławek J. Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease. Neurol Neurochir Pol 2009; 43:272-285.
20. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22:195-201. (Pubitemid 32244306)
21. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000; 55:437-440. (Pubitemid 30650089)
22. Todorovic Z, Dzoljic E, Novakovic I, Mirkovic D, Stojanovic R, Nesic Z, et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci 2006; 248:56-61. (Pubitemid 44647314)
23. Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-dopa, homocysteine, and MTHFR genotype. J Neurol Sci 2003; 207:19-23. (Pubitemid 36287098)
24. Białecka M, Droździk M, Honczarenko K, Gawroń ska-Szklarz B, Stankiewicz J, Dabrowska E, et al. Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population. Eur Neurol 2005; 53:68-73. (Pubitemid 40868704)
25. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, et al. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the termolabile variant of the enzyme. Biochemistry 1995; 34:4202-4210.
26. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314:1930-1933. (Pubitemid 46026115)
27. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50:2766-2774. (Pubitemid 39209513)
28. Fong CS, Shyu HY, Shieh JC, Fu YP, Chin TY,Wang HW, et al. Association of MTHFR, MTR, and MTRR polymorphisms with Parkinson's disease among ethnic Chinese in Taiwan. Clin Chim Acta 2011; 412:332-338.
29. Hughes AJ, Daniel SE, Blankson SE, Lees AL. A clinicopathological study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50:140-148. (Pubitemid 23054795)
30. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427-442.
31. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
32. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571.
33. Mungas D, Marshall S, Weldon W, Haan M, Reed BR. Age and education correction of Mini-Mental State Examination for English and Spanish speaking elderly. Neurology 1996; 46:700-706. (Pubitemid 26099636)
34. Brzezinski J, Gaul M, Hornowska E, Jaworowska A, Machowski A, Zakrzewska M. WAIS-R(PL)-Wechsler Adult Intelligence Scale-renormalized.Warsaw, Poland: Pracownia Testów Psychologicznych; 2004.
35. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. New York: Oxford University Press; 2004.
36. Kadzielawa D, Mroziak J, Bolewska A, Osiejuk E. Halstead-Reitan Neuropsychological Battery. Manual. Warsaw, Poland: Psychological Test Laboratory of the Polish Psychological Association; 1990.
37. Jaworowska A. Wisconsin Card Sorting Test (WCST)-manual. Warsaw: Laboratory of Psychological Tests; 2002.
38. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria in Parkinson's disease associated with dementia. Mov Disord 2007; 12:1689-1707. (Pubitemid 47597592)
39. Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics 2008; 18:815-821.
40. Kurzawski M, Pawlik A, Safranow K, Herczynska M, Drozdzik M. 677C> T and 1298A >C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics 2007; 8:1551-1559. (Pubitemid 350286399)
41. Kurzawski M, Stefankiewicz J, Kurzawa R, Gó rnik W, Baczkowski T, Drozdzik M. The SLC19A1 80G>A polymorphism is not associated with male infertility. Biomarkers 2010; 15:217-220.
42. Dangour AD, Allen E, Clarke R, Elbourne D, Fasey N, Fletcher AE, et al. A randomized controlled trial investigating the effect of vitamin B12 supplementation on neurological function in healthy older people: the Older People and Enhanced Neurological function (OPEN) study protocol [ISRCTN54195799]. Nutr J 2011; 22:1-8.
43. Moore E, Mander A, Ames D, Carne R, Sanders K, Watters D. Cognitive impairment and vitamin B12: a review. Int Psychogeriatr 2012; 6:1-16.
44. Hooshmand B, Solomon A, Ka° reholt I, Rusanen M, Hä nninen T, Leiviskä J, et al. Associations between serum homocysteine, holotranscobalamin, folate and cognition in the elderly: a longitudinal study. J Intern Med 2012; 271:204-212.
45. Sunder-Plassmann G, Fö dinger M. Genetic determinants of the homocysteine level. Kidney Int Suppl 2003; 84:S141-S144. (Pubitemid 36513396)
46. Fö dinger M, Buchmayer H, Heinz G, Papagiannopoulos M, Kletzmayr J, Rasoul-Rockenschaub S, et al. Effect of MTHFR 1298A-C and MTHFR 677C-T genotypes on total homocysteine, folate, and vitamin B(12) plasma concentrations in kidney graft recipients. J Am Soc Nephrol 2000; 11:1918-1925.
47. Yuan RY, Sheu JJ, Yu JM, Hu CJ, Tseng IJ, Ho CS, et al. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. J Neurol Sci 2009; 287:64-68.
48. Van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 21:1070-1071.
49. Van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62:1044-1051. (Pubitemid 28199004)
50. Wald DS, Kasturiratne A, Simmonds M. Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement 2011; 7:412-417.
51. Haan MN, Miller JW, Aiello AE,Whitmer RA, Jagust WJ, Mungas DM, et al. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr 2007; 85:511-517. (Pubitemid 46220956)
52. Isobe C, Abe T, Terayama Y. L-dopa therapy increase homocysteine concentration in cerebrospinal fluid from patients with Parkinson's Disease. J Clin Neurosci 2010; 17:717-721.
53. Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005; 43:1107-1110. (Pubitemid 41581969)
54. Hoogland J, de Bie RM,Williams-Gray CH, Muslimović D, Schmand B, Post B. Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease. Mov Disord 2010; 25:2550-2554.
55. Ford AH, Flicker L, Alfonso H, Hankey GJ, Norman PE, van Bockxmeer FM, et al. Plasma homocysteine and MTHFRC677T polymorphism as risk factors for incident dementia. J Neurol Neurosurg Psychiatry 2011; 83:70-75.
56. Camicioli RM, Bouchard TP, Somerville MJ. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov Disord 2009; 24:176-182.
57. Zhang MY, Miao L, Li YS, Hu GY. Meta-analysis of the methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to Alzheimer's disease. Neurosci Res 2010; 68:142-150.
58. Zhu BT. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis. Histol Histopathol 2002; 17:1283-1291.
59. Zhu BT. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002; 3:321-349. (Pubitemid 34625043)
60. Nissinen E, Nissinen H, Larjonmaa H, Väänänen A, Helkamaa T, Reenilä I, et al. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 2005; 112:1213-1221. (Pubitemid 41215924)
61. Lee MS, Lyoo CH, Ulmanen I, Syvänen AC, Rinne JO. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 2001; 298:131-134. (Pubitemid 32040894)